Oral Contraceptives and Venous Thromboembolism: Which Are the Safest Preparations Available?

Abstract

Oral contraceptive therapy is associated with a fourfold increased risk of venous thromboembolism as compared with agematched non-users. The composition of oral contraceptives has varied considerably during the past two to three decades. The estrogen content (ethinylestradiol) has decreased and is now less than 0.03 mg/pill. This was done on the assumption that estrogen was the main culprit for thrombotic complications. Subsequently it was found that the progestins contained in the pill could also play a thrombogenic role. This was particularly maintained to be so for the third-generations progestins, namely gestodene or desogestrel. These gonane progestins have been widely used since the early 1990s, because they appeared to have a lesser androgenic effect. A careful and impartial evaluation of the literature seems to indicate that third-generation progestins are associated with a slight increase in thrombotic risk. However, the significance of this difference remains to be proven. In fact, a relative risk of only two in retrospective studies may have limited effect and disappear in prospectives studies. The role of associated risk factors, both congenital and acquired, has been often overlooked in most of the papers dealing with the subject. This may be important. Preparations containing third-generation progestins are probably associated with a slight increase in thrombosis risk. It is the responsibility of the physician to select the preparation most suited for a given patient. As a general rule it may be safe to start with a preparation containing second-generation progestins. However there is no need for “a pill scare” and it does not seem justified to have women already taking pills containing third-generation progestins to switch to other preparations. If a woman taking preparations containing third-generation progestins experience symptoms, it is probably safe to advise that patient not to take any oral contraceptive pill in the future, regardless of the type. The same is true for women who experience symptoms while taking second-generation progestins preparations.

Keywords

Estrogen Oral contraceptives Progestin Venous thromboembolism

References

1. Vessey M , Mant D , Smith A , et al. Oral contraceptives and venous thromboembolism: Finding in a large prospective study. Br Med J 1986;292:526-526.

2. Helmrich SP , Rosemberg L , Kaufman DW , et al. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol 1987;69:91-91.

3. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception . Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. Lancet 1995;346:1575-1575.

4. Vandenbroucke JP , Rosing J , Bloemenkamp KW , et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527-1527.

5. Girolami A , Simioni P , Zanardi S . The role of drugs, particularly oral contraceptives in triggering thrombosis in congenital defects of coagulation inhibitors: A study of six patients. Blood Coagul Fibrinol 1991;2:673-673.

6. Prandoni P , Lensing AW , Cogo A , et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-1.

7. Carter CJ . The natural history and epidemiology of venous thrombosis. Prog Cardiovasc Dis 1994;36:423-423.

8. Kluft C . Renewed interest in haemostasis changes induced by oral contraceptives (OCs). Thromb Haemost 2000;84:1-1.

9. Winkler UH . Blood coagulation and oral contraceptives. A critical review. Contraception 1998;57:203-203.

10.

10. Girolami A , Stevanato F , Lazzaro AR . Bilateral ileofemoral thrombophlebitis after ten contraceptive pills in a 25-year-old woman with antithrombin III deficiency. Acta Haematol 1988;79:118-118.

11.

11. Girolami A , Simioni P , Sartori MT , et al. Oral contraceptives caused thrombosis in a monoovular twin protein C deficiency, while the other, without medication, remained asymptomatic. Blood Coagul Fibrinolysis 1992;3:119-119.

12.

12. Girolami A , Simioni P , Scarano L , et al. Patient with APCresistance as compared with other clotting inhibitor deficiencies show a later onset of venous thrombosis during oral contraception. Clin Appl Thromb Hemost 1995;1:118-118.

13.

13. Girolami A , Tormene D , Vianello F . Prothrombotic activity of oral contraceptives in patients with congenital thrombophilia varies with the defect. Clin Appl Thromb Hemost 2001;7:76-76.

14.

14. Walker AM . Newer oral contraceptives and the risk of venous thromboembolism. Contraception 1998;57:169-169.

15.

15. Skegg DC . Third-generation oral contraceptives. BMJ 2000;321:190-190.

16.

16. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception . Effect of different progestagens in low estrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-1582.

17.

17. Committee on Safety of Medicine: Combined oral contraceptives containing desogestrel or gestodene and the risk of venous thromboembolism. Curr Probl Pharmacovig 1999;25:12-12.

18.

18. Helmerhorst FM , Bloemenkamp KW , Rosendaal FR , Vandenbroucke JP . Oral contraceptives and thrombotic disease: Risk of venous thromboembolism. Thromb Haemost 1997;78:327-327.

19.

19. Jick H , Jick SS , Gurewich V , et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-1589.

20.

20. Farley TM , Collins J , Schlesselman JJ . Hormonal contraception and risk of cardiovascular disease. An international perspective. Contraception 1998;57:211-211.

21.

21. Farley TM , Meirik O , Collins J . Cardiovascular disease and combined oral contraceptives: Reviewing the evidence and balancing the risks. Hum Reprod Update 1999;5:721-721.

22.

22. Farmer RD , Lawrenson RA , Thompson CR , et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-83.

23.

23. Spitzer WO , Lewis MA , Heinemann LA , et al. Third-generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996;312:83-83.

24.

24. Farmer RD , Williams TJ , Simpson EL , et al. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: Analysis of general practice research database. Br Med J 2000;321:477-477.

25.

25. Suissa S , Blais L , Spitzer WO , et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997;56:141-141.

26.

26. Greaves M , Preston FE . Rebuttal to: Oral contraceptives and venous thromboembolism. Thromb Haemost 2001;85:932-932.

27.

27. O'Brien PA . The third-generation oral contraceptive controversy. The evidence shows they are less safe than second generation pills. Br Med J 1999;319:795-795.

28.

28. Martinelli I , Taioli E , Bucciarelli P , et al. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999;19:700-700.

29.

29. Girolami A , Tormene D , Simioni P , et al. Long-term use of oral contraceptive therapy in women with the prothrombin 20210 g-a polymorphism without thrombotic complications: A study of 13 women (12 heterozygotes and 1 homozygote). Thromb Res 2001;102:205-205.

30.

30. Girolami A , Simioni P , Tormene D . APC resistance, oral contraceptive therapy, and deep vein thrombosis: Settled and unsettled problems. Haematologica 2000;85:225-225.

31.

31. Girolami A , Simioni P , Girolami B , et al. Homozygous patients with APC resistance may remain paucisymptomatic or asymptomatic during oral contraception. Blood Coagul Fibrinolysis 1996;7:590-590.

32.

32. Sanson BJ , Simioni P , Tormene D , et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: A prospective cohort study. Blood 1999;94:3702-3702.